Properties (71)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:advertising |
expansion plans
|
| gptkbp:businessModel |
biopharmaceutical development
|
| gptkbp:CEO |
Charles_J._Homcy
|
| gptkbp:clinicalTrials |
multiple locations
collaborative studies Phase 3 trials ongoing studies treatment protocols publicly traded company Phase 1, Phase 2, Phase 3 published in peer-reviewed journals novel compounds thromboembolic disorders |
| gptkbp:collaborations |
gptkb:Takeda_Pharmaceutical_Company
academic institutions collaborative research |
| gptkbp:community_engagement |
healthcare_initiatives
|
| gptkbp:community_service |
safety and efficacy
support programs |
| gptkbp:competitors |
industry trends
|
| gptkbp:drugInterdiction |
gptkb:European_Medicines_Agency
advanced technologies diverse candidates adverse event monitoring injectable and oral |
| gptkbp:employeeCount |
approximately 200
|
| gptkbp:enrollment |
clinical trials
various demographics |
| gptkbp:feedback |
improved patient care
measured improvements |
| gptkbp:financialPerformance |
quarterly reports
|
| gptkbp:focus |
innovative therapies for blood-related disorders
|
| gptkbp:founded |
2003
|
| gptkbp:founder |
William_Lis
|
| gptkbp:funding |
philanthropic contributions
grants and investments |
| gptkbp:headquarters |
gptkb:South_San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Portola Pharmaceuticals
|
| gptkbp:investmentFocus |
over $300 million
Venture capital firms public disclosures |
| gptkbp:leadership |
experienced management team
|
| gptkbp:market |
gptkb:United_States
Europe approximately $1 billion |
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer biotech companies |
| gptkbp:patentCitation |
multiple patents in drug development
|
| gptkbp:products |
Bevyxxa
Cerdulatinib Andexxa |
| gptkbp:publications |
research findings
|
| gptkbp:regulatoryCompliance |
new drug applications
FDA_regulations FDA_approval_for_Andexxa |
| gptkbp:research |
gptkb:Dr._John_Doe
|
| gptkbp:research_areas |
hematology
targeted therapies new treatment options oncology and hematology |
| gptkbp:research_focus |
anticoagulants
diagnostic tools immune-oncology |
| gptkbp:revenue |
$100 million (2020)
|
| gptkbp:stockExchange |
gptkb:NASDAQ
PTLA |
| gptkbp:supportRole |
experts in hematology
|
| gptkbp:tributaryOf |
multiple drug candidates
|